Form 424B3 Panbela Therapeutics,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil slips on weaker demand outlook and higher US stocks amid supply disruptions
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
H.C. Wainwright Downgrades Panbella Therapeutics (PBLA) to Neutral
May 16, 2024 11:31 AM EDTH.C. Wainwright analyst Joseph Pantginis downgraded Panbella Therapeutics (NASDAQ: PBLA) from Buy to Neutral.
The analyst comments "Yesterday after the close, Panbela announced 1Q24 results, posting 1Q24 EPS of ($2.28) compared with our estimate of ($1.23) and consensus of ($1.62). The company ended the quarter with $262,000 in cash. Per management, current cash burn... More
